Aurora Cannabis Launches Black Jelly Strain in Poland to Expand Product Portfolio

Aurora Cannabis Expands Product Portfolio with Launch of Black Jelly in Poland

Aurora Cannabis Inc., a leading player in the global medical cannabis sector, has announced the launch of its proprietary cultivar, Black Jelly, in Poland, effective December 11, 2025. This strategic move enhances Aurora's offerings in a rapidly growing European market, reflecting the company's commitment to providing high-quality medical cannabis products. Black Jelly is a high-THC sativa strain, boasting an impressive cannabinoid profile with 27% THC and less than 1% CBD. The unique strain, derived from Alien Cake 3030 and T037, is cultivated in Aurora's accredited Canadian facilities and is characterized by its dense, visually striking flowers that display vibrant green and orange hues. The cultivar's distinct terpene profile, featuring sweet black liquorice and fruity notes, sets it apart in a competitive landscape.

Andreas Dotterweich, Senior VP of Europe at Aurora Cannabis, underscores the company's dedication to delivering reliable medical cannabis options tailored to the needs of prescribers and patients. With Black Jelly joining the ranks of other esteemed products like Farm Gas and Sourdough in the Cannabis flos Aurora brand portfolio, Aurora demonstrates its commitment to innovation and quality. The introduction of Black Jelly signifies not only an expansion of Aurora's product lineup but also its strategic positioning in Poland's evolving medical cannabis landscape, where the company aims to leverage over a decade of experience in global markets.

Beyond its focus on medical cannabis, Aurora Cannabis also has a presence in the consumer market and holds a controlling interest in Bevo Farms Ltd., a leading supplier of propagated agricultural plants in North America. This diversification within the cannabis sector showcases Aurora's aim to improve lives through cannabis while continually innovating and expanding its offerings across Canada, Europe, Australia, and New Zealand. As the company pushes forward, it remains committed to its mission of enhancing the quality of life for patients worldwide.